West Cancer Center

PANCREATIC: METASTATIC: FIRST-LINE: Actuate 1801

Phase 1/2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3β) Inhibitor, as a Single Agent and Combined With Chemotherapy, in Patients With Refractory Hematologic Malignancies or Solid Tumors (pancreatic cohort)

Title

Actuate 1801 (Pancreatic GSK-3B inhibitor)

Study Title

Site Link

NCT03678883

Malignancy

Pancreatic cancer

Stage

Stage 4

Disease Setting

Metastatic/Palliative

Line Of Therapy

1st Line

Investigational Agent

9-ING-41

Drug Class

GSK-3beta inhibitor

Brad Somer, MD

Sponsor

Actuate Therapeutics Inc.

Phase

Phase 2

Status

Open to Enrollment

Key Eligibility Criteria

Key Eligibility Criteria Details

Pathologically or cytologically confirmed metastatic pancreatic cancer
Previously untreated with systemic agents in recurrent/metastatic setting
Measurable disease
May have received adjuvant therapy if given at least 6 months before study enrollment
No significant cardiovascular impairment
No other malignancy

Objective

Primary
- 1-year survival

Assessment Frequency

Assessment Frequency 2

Assessment Frequency Link

Path

Pancreatic adenocarcinoma

Dosing Frequency

Control Agents

Study Protocol

Randomized